source
- J&J to acquire Ollin Biosciences for up to $3.3 billion, adding eye disease drug to its portfolioJohnson & Johnson announced it will purchase Ollin Biosciences, a biotechnology startup developing an eye disease therapy. The transaction includes an upfront payment of $2.2 billion and up to $1.…
- FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissionerThe FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…